Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SPINK1



This biomarker is also known as:
  • PCTT,
  • PSTI,
  • Spink3,
  • Tumor-Associated Trypsin Inhibitor,
  • TCP,
  • TATI,
  • Serine Protease Inhibitor, Kazal Type 1,
  • Pancreatic Secretory Trypsin Inhibitor,
  • Serine Protease Inhibitor, Kazal-Type 1,
  • Serine Peptidase Inhibitor, Kazal Type 1,

View in BioMuta


SPINK1 is a trypsin inhibitor, which is secreted from pancreatic acinar cells into pancreatic juice. Its physiological function is to prevent the trypsin-catalyzed premature activation of zymogens within the pancreas. Mutations in SPINK1 are associated with hereditary pancreatitis and tropical calcific pancreatitis.


QA State: Curated
Type: Gene
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


High levels of SPINK1 have been associated with a greater rate of prostate cancer recurrence.

Performance Comment

Increased SPINK1 transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.